EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of m6A-related lncRNAs prognostic signature for predicting immunotherapy response in cervical cancer

Quanhong Ping, Qi Chen, Na Li

SLAS Technology · 2024

DOI: 10.1016/j.slast.2024.100210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLAS Technology, 2024. Verfasst von Quanhong Ping und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dept. Gynecologic Oncology, Tianjin Central Hospital of Gynecology Obstetrics/Tianjin Key Laboratory of human development and reproductive regulation…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, RNA, Long Noncoding, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Science and Technology Program, Tianjin Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: N6-methylandenosine-related long non-coding RNAs (m6A-related lncRNAs) play a crucial role in the cancer progression and immunotherapeutic efficacy. The potential function of m6A-related lncRNAs signature in cervical cancer has not been systematically clarified. METHODS: RNA-seq and the clinical data of cervical cancer were extracted from The Cancer Genome Atlas. All of the patients were randomly classified into training and testing cohorts. The m6A-related lncRNAs prognostic model was constructed by LASSO regression using data in the training cohort.The predictive value of the signature was validated in the whole cohort and testing cohort. Cervical cancer patients were divided into low- and high-risk subgroups by the median value of risk scores. Kaplan-Meier analysis, principal-component analysis (PCA), functional enrichment annotation, and nomogram were used for further evaluation. We also examined the immune response and potential drug sensitivity targeting this model. RESULTS: Seventy-nine prognostic m6A-related lncRNAs were screened. The risk model comprising four m6A-related lncRNAs (AL139035.1, AC015922.2, AC073529.1, AC008124.1) was identified and verified as an independent prognostic predictor of cervical cancer. A nomogram based on age, tumor grade, clinical stage, TNM stage, and four m6A-related lncRNAs risk signatures was generated. It displayed good accuracy and reliability in predicting the overall survival of patients with CC. Based on our risk model, cervical cancer patients with potential immunotherapy benefits from the candidate drugs could be effectively screened. CONCLUSION: The four m6A-related lncRNAs signature may provide new targets and allow the prediction of immunotherapy response, which can assist developing individualized treatment for cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsRNA, Long NoncodingImmunotherapyHumansFemalePrognosisGene Expression Regulation, NeoplasticBiomarkers, TumorAdenosineGene Expression ProfilingMiddle AgedNomograms

Stichwörter der Autor:innen

Cervical cancerImmunotherapyLong noncoding RNAsN6-methylandenosinePrognostic signature

Substanzen

RNA, Long NoncodingBiomarkers, TumorAdenosineN-methyladenosine

Autor:innen und Institutionen

  • Dept. Gynecologic Oncology, Tianjin Central Hospital of Gynecology Obstetrics/Tianjin Key Laboratory of human development and reproductive regulation, Nankai University Maternity Hospital, Tianjin, China.
  • Dept. Gynecologic Oncology, Tianjin Central Hospital of Gynecology Obstetrics/Tianjin Key Laboratory of human development and reproductive regulation, Nankai University Maternity Hospital, Tianjin, China. Electronic add…

Förderung

  • Tianjin Science and Technology Program
  • Tianjin Municipal Health Commission

Zitieren

APA

Ping, Q., Chen, Q., & Li, N. (2024). Identification of m6A-related lncRNAs prognostic signature for predicting immunotherapy response in cervical cancer. SLAS Technology. https://doi.org/10.1016/j.slast.2024.100210

Vancouver

Ping Q, Chen Q, Li N. Identification of m6A-related lncRNAs prognostic signature for predicting immunotherapy response in cervical cancer. SLAS Technology. 2024. doi:10.1016/j.slast.2024.100210

BibTeX
@article{Ping2024,
  author = {Ping, Quanhong and Chen, Qi and Li, Na},
  title = {Identification of m6A-related lncRNAs prognostic signature for predicting immunotherapy response in cervical cancer},
  journal = {SLAS Technology},
  year = {2024},
  doi = {10.1016/j.slast.2024.100210}
}
Kostenlos starten →